Bruce Wendel

Abraxis Bioscience, Inc. develops therapeutics for cancer, infectious diseases and other critical illnesses. Its development platform uses nanoparticle albumin-bound technology to deliver drugs to tumors that produce SPARC. Abraxene, the first protein-based nanoparticle chemotherapeutic compound, is FDA approved for treating metastatic breast cancer. Abraxis Bioscience is focused on expanding the use of Abraxene and developing other drug candidates utilizing the same technology. Abraxene is approved for marketing in over 35 countris and the company has manufacturing facilities in the United States and Switzerland. Abraxis Bioscience was organized in 2007 from the oncology and research businesses of American Pharmaceutical Partners, Inc. and is headquartered in Los Angeles, CA.

American Pharmaceutical Partners, Inc. is engaged in to developing, manufacturing and marketing injectable pharmaceutical products. The company produces generic injectable pharmaceutical products in more than 300 dosages and formulations. The company focuses mainly in the oncology, anti-infective and critical care markets. The company is located in Schaumburg, IL.

IVAX LLC discovers, develops, manufactures, and markets generic pharmaceuticals, respiratory drugs, and cancer treatments. It offers drugs for the treatment of multiple sclerosis, brain cancer, asthma, and epilepsy. The company was founded by Phillip Frost and Jane H. Hsiao in 1987 and is headquartered in Weston, FL.

Abraxis Health is establishing as a fully-integrated, next-generation, evidence-based, and personalized healthcare company. It plans to develop a proprietary model for the delivery of healthcare. Abraxis Health is designing and acquiring the necessary infrastructure and plans to acquire and internally develop the hardware and software modules to organize and integrate the data streams that form the foundation of an interactive database. The firm will develop, test, and validate diagnostics and drugs to target pre-selected patients based on molecular profiles that predict drug response to particular therapeutics.

Abraxis BioScience, Inc. manufactures specialty pharmaceutical products. The company develops, manufactures and markets injectable products and leverages revolutionary technology such as its nab(TM) platform to discover and deliver breakthrough therapeutics that transform the treatment of cancer and other life threatening diseases. The company is located in Schaumburg, IL